These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 32357861

  • 1. Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.
    Tran TV, Dang KX, Pham QH, Nguyen UD, Trinh NTT, Hoang LV, Ho SA, Nguyen BV, Nguyen DT, Trinh DT, Tran DN, Orpana A, Stenman UH, Stenman J, Ho TH.
    BMC Cancer; 2020 May 01; 20(1):368. PubMed ID: 32357861
    [Abstract] [Full Text] [Related]

  • 2. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G, Mikhno N, Khabalova T, Svyatchenko S, Mostovich L, Shevchenko S, Gulyaeva L.
    Surg Oncol; 2018 Dec 01; 27(4):702-708. PubMed ID: 30449496
    [Abstract] [Full Text] [Related]

  • 3. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K.
    Indian J Cancer; 2017 Dec 01; 54(1):372-378. PubMed ID: 29199726
    [Abstract] [Full Text] [Related]

  • 4. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct 01; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 5. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, Wang L.
    Pathol Res Pract; 2018 Feb 01; 214(2):303-307. PubMed ID: 29254799
    [Abstract] [Full Text] [Related]

  • 6. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb 01; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 7. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
    Hay R, MacRae E, Barber D, Khalil M, Demetrick DJ.
    Arch Pathol Lab Med; 2007 Sep 01; 131(9):1361-7. PubMed ID: 17824790
    [Abstract] [Full Text] [Related]

  • 8. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma.
    Wang Z, Sun K, Jing C, Cao H, Ma R, Wu J.
    J Clin Lab Anal; 2019 Jul 01; 33(6):e22902. PubMed ID: 31021028
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun 01; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

  • 10. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients.
    Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, Sameer Aga S.
    J Clin Lab Anal; 2021 Feb 01; 35(2):e23628. PubMed ID: 33305405
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M, Ugalde Olano A, Fuertes Thomas E, Oleaga Alday A.
    Endocrinol Diabetes Nutr; 2017 Feb 01; 64(2):75-81. PubMed ID: 28440781
    [Abstract] [Full Text] [Related]

  • 12. The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing.
    Yeo MK, Jung MK, Lee SY, Lee YM, Hur GM, Kim JM.
    J Clin Pathol; 2017 Mar 01; 70(3):260-265. PubMed ID: 27543599
    [Abstract] [Full Text] [Related]

  • 13. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H, Li W, Yan P, Bundschuh R, Killian JA, Labanowska J, Brock P, Shen R, Heerema NA, de la Chapelle A.
    Thyroid; 2018 Jun 01; 28(6):748-754. PubMed ID: 29768105
    [Abstract] [Full Text] [Related]

  • 14. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.
    Zhonghua Zhong Liu Za Zhi; 2011 May 01; 33(5):354-7. PubMed ID: 21875464
    [Abstract] [Full Text] [Related]

  • 15. Imbalance in DNA repair machinery is associated with BRAFV600E mutation and tumor aggressiveness in papillary thyroid carcinoma.
    Lutz BS, Leguisamo NM, Cabral NK, Gloria HC, Reiter KC, Agnes G, Zanella V, Meyer ELS, Saffi J.
    Mol Cell Endocrinol; 2018 Sep 05; 472():140-148. PubMed ID: 29229408
    [Abstract] [Full Text] [Related]

  • 16. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May 05; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 17. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.
    Clin Endocrinol (Oxf); 2012 Nov 05; 77(5):780-6. PubMed ID: 22702340
    [Abstract] [Full Text] [Related]

  • 18. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ.
    Endocr Relat Cancer; 2012 Dec 05; 19(6):779-84. PubMed ID: 22997209
    [Abstract] [Full Text] [Related]

  • 19. Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.
    Sato A, Tanabe M, Tsuboi Y, Niwa T, Shinozaki-Ushiku A, Seto Y, Murakami Y.
    Thyroid; 2021 Dec 05; 31(12):1822-1828. PubMed ID: 34541884
    [Abstract] [Full Text] [Related]

  • 20. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD, Fu SS, Chen JY, Lee CH, Chau WK, Cheng CW, Wang YH, Lin YF, Fang WF, Tang KT.
    Thyroid; 2016 May 05; 26(5):691-704. PubMed ID: 26914762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.